Neuphoria Therapeutics Inc. (NEUP) — 8-K Filings

8-K Filings (16)

• Neuphoria Therapeutics Faces Delisting Notice — Dec 18, 2025 Risk: high
  Neuphoria Therapeutics Inc. filed an 8-K on December 18, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and a
• Neuphoria Therapeutics Files 8-K on Shareholder Vote Matters — Dec 17, 2025 Risk: medium
  Neuphoria Therapeutics Inc. filed an 8-K on December 17, 2025, reporting on a submission of matters to a vote of security holders. The filing indicates that the
• Neuphoria Therapeutics Inc. Files 8-K with Key Corporate Updates — Oct 27, 2025 Risk: medium
  Neuphoria Therapeutics Inc. filed an 8-K on October 27, 2025, reporting on several key events. These include entering into a material definitive agreement, mate
• Neuphoria Therapeutics Files 8-K — Oct 20, 2025 Risk: low
  Neuphoria Therapeutics Inc. filed an 8-K on October 20, 2025, reporting other events and financial statements. The company, formerly known as Bionomics Limited/
• Neuphoria Therapeutics Faces Delisting Concerns — Sep 16, 2025 Risk: high
  Neuphoria Therapeutics Inc. filed an 8-K on September 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The filing indic
• Neuphoria Therapeutics Faces Delisting Notice — Jul 18, 2025 Risk: high
  Neuphoria Therapeutics Inc. filed an 8-K on July 18, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, formerly
• Neuphoria Therapeutics Files 8-K on Financials — May 20, 2025 Risk: low
  Neuphoria Therapeutics Inc. filed an 8-K on May 20, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
• Neuphoria Therapeutics Files 8-K — Jan 14, 2025 Risk: medium
  Neuphoria Therapeutics Inc. filed an 8-K on January 14, 2025, reporting an "Other Event" that occurred on January 10, 2025. The filing does not provide specific
• Bionomics Ltd. Files 8-K: Agreements, Delisting Notice, Equity Sales — Dec 23, 2024 Risk: high
  Bionomics Limited announced on December 23, 2024, that it has entered into a material definitive agreement. The company also provided notice of potential delist
• Bionomics Limited Files 8-K — Dec 16, 2024 Risk: low
  Bionomics Limited filed an 8-K on December 16, 2024, reporting other events and financial statements/exhibits. The filing does not contain specific details abou
• Bionomics Limited Files 8-K — Dec 12, 2024 Risk: low
  Bionomics Limited filed an 8-K on December 11, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing does not
• Bionomics Limited Enters Material Definitive Agreement — Nov 21, 2024 Risk: medium
  Bionomics Limited entered into a material definitive agreement on November 18, 2024. The filing does not disclose specific details of the agreement or any assoc
• Bionomics Limited Files 8-K — Nov 8, 2024 Risk: low
  Bionomics Limited filed an 8-K on November 8, 2024, to report other events and financial statements/exhibits. The filing does not contain specific details about
• Bionomics Board Shakeup: New Director, Chairman Appointed — Oct 10, 2024 Risk: medium
  Bionomics Limited announced on October 9, 2024, the departure of Director Dr. Steven Michael, effective immediately. The company also appointed Dr. Paul R. Edic
• Bionomics Limited Files 8-K for Material Definitive Agreement — Oct 2, 2024 Risk: medium
  On October 1, 2024, Bionomics Limited entered into a material definitive agreement. The company, incorporated in Australia, filed a Form 8-K with the SEC to rep
• Bionomics Faces Nasdaq Delisting Warning — Jul 16, 2024 Risk: medium
  Bionomics Limited announced on July 11, 2024, that it received a notice from the Nasdaq Stock Market regarding its failure to meet the minimum bid price require

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX